{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:16:21Z","timestamp":1787991381174,"version":"build-2784847793"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.obpill.2026.100300","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:24:39Z","timestamp":1783700679000},"page":"100300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-9175","authenticated-orcid":false,"given":"Theresa Hunter","family":"Gibble","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Leith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya Kokil","family":"Raikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Era","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Artime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.obpill.2026.100300_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/oby.22378","article-title":"Obesity as a disease: the obesity society 2018 position statement","volume":"27","author":"Jastreboff","year":"2019","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2026.100300_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American association of Clinical Endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.obpill.2026.100300_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"S 01","key":"10.1016\/j.obpill.2026.100300_bib6","first-page":"P12","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4)","volume":"19","author":"Aronne","year":"2024","journal-title":"Diabetol Stoffwechs"},{"issue":"11","key":"10.1016\/j.obpill.2026.100300_bib7","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.obpill.2026.100300_bib8","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: disease-Specific Programmes\u2013a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"10.1016\/j.obpill.2026.100300_bib9","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","article-title":"Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease specific programmes","volume":"39","author":"Anderson","year":"2023","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"10.1016\/j.obpill.2026.100300_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010352","article-title":"Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease Specific programme","volume":"6","author":"Babineaux","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.obpill.2026.100300_bib11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015","author":"Higgins","year":"2016","journal-title":"Diabetes, Metab Syndrome Obes Targets Ther"},{"key":"10.1016\/j.obpill.2026.100300_bib12","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.2147\/PPA.S433662","article-title":"Improving assessment of adherence behaviors and drivers: targeted literature review and concept elicitation interviews in multiple countries and disease populations","author":"Bentley","year":"2024","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.obpill.2026.100300_bib13","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.2147\/PPA.S358046","article-title":"Qualitative interviews to support development and cognitive debriefing of the adelphi adherence questionnaire (ADAQ\u00a9): a patient-reported measure of medication adherence developed for use in a range of diseases, treatment modalities, and countries","author":"Bentley","year":"2022","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.obpill.2026.100300_bib14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s41687-024-00789-7","article-title":"Psychometric evaluation of the adelphi adherence questionnaire (ADAQ\u00a9) in adults with osteoarthritis","volume":"8","author":"Clarke","year":"2024","journal-title":"J Patient-Rep Outcomes"},{"issue":"1","key":"10.1016\/j.obpill.2026.100300_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12889-024-21061-z","article-title":"Prevalence of complications and comorbidities associated with obesity: a health insurance claims analysis","volume":"25","author":"Bae","year":"2025","journal-title":"BMC Public Health"},{"issue":"18","key":"10.1016\/j.obpill.2026.100300_bib16","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.1017\/S1368980021003694","article-title":"Impact of elevated BMI and types of comorbid conditions on health-related quality of life in a nationally representative US sample","volume":"24","author":"Le","year":"2021","journal-title":"Public Health Nutr"},{"issue":"11","key":"10.1016\/j.obpill.2026.100300_bib17","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1007\/s12325-024-02932-8","article-title":"The correlation between body mass index and health-related quality of life: data from two weight loss intervention studies","volume":"41","author":"Kral","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.obpill.2026.100300_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejim.2021.01.019","article-title":"Patient motivation to lose weight: importance of healthcare professional support, goals and self-efficacy","volume":"91","author":"Dicker","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"Supplement_1","key":"10.1016\/j.obpill.2026.100300_bib19","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad114.112","article-title":"SAT664 obesity and overweight diagnosis, physician prescription and patient filling of anti-obesity medications in US","volume":"7","author":"Ezendu","year":"2023","journal-title":"J Endocr Soc"},{"issue":"5","key":"10.1016\/j.obpill.2026.100300_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285197","article-title":"Weight loss efficiency and safety of tirzepatide: a systematic review","volume":"18","author":"Lin","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.obpill.2026.100300_bib21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12020-024-03896-z","article-title":"Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: an updated systematic review and meta-analysis including the latest SURMOUNT-2 trial","volume":"86","author":"Qin","year":"2024","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.obpill.2026.100300_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pcd.2025.03.008","article-title":"The promise of tirzepatide: a narrative review of metabolic benefits","volume":"19","author":"Sokary","year":"2025","journal-title":"Prim Care Diabet"},{"key":"10.1016\/j.obpill.2026.100300_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/2050312118807618","article-title":"Beyond weight loss: a qualitative exploration of participant expectations and strategies for measuring progress during a weight management program","volume":"6","author":"Ingels","year":"2018","journal-title":"SAGE Open Med"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:30:26Z","timestamp":1787988626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368126000562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":21,"alternative-id":["S2667368126000562"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100300","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100300"}}